Kornimate/medical-research-clean huggingface dataset:
novel biomarkers in assessment of interstitial lung disease associated with rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis; Interstitial Lung Disease

Summary: - assess kl-6 and calprotectin as novel biomarkers for diagnosis of ild among rheumatoid arthritis patients

rheumatoid arthritis (ra) is a systemic autoimmune disease characterized by small joint synovitis that is estimated to affect 0.3% to 1% of the global population. extraarticular disease may occur in up to 50% of patients with ra, with pulmonary manifestations among the most common extraarticular features. interstitial lung disease (ild) clinically affects up to 10% of patients with ra and subclinically affects up to 40%. ra-ild typically presents as a usual interstitial pneumonia (uip) or nonspecific interstitial pneumonia pattern. diagnosis requires a thorough evaluation, including laboratory and imaging studies; pulmonary function testing (pft); medication review; occasionally, tissue histopathology; and frequently, multidisciplinary input. prompt recognition of ra-ild is crucial because it warrants close monitoring and often necessitates therapeutic alterations. biomarkers are a promising area of investigation in ra-ild because they have the potential to advance pathophysiologic understanding and elucidate therapeutic targets, improve disease identification and diagnostic accuracy, facilitate prognostication, and inform treatment decisions. although imaging and histopathology have important roles that are unlikely to be replaced by biomarkers, they can be nonspecific in ra-ild, can be impractical to obtain in certain settings, and cannot be scaled for population health efforts. calprotectin belongs to the s-100 proteins produced by neutrophils, which likely contribute to ipf pathogenesis. calprotectin is a well-established biomarker in inflammatory bowel diseases.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of rheumatoid arthritis, age \> 18 years. exclusion criteria: * patients who refuse to participate in the study, * patients with evidence of worsening or exacerbation of ra over the previous 6 months, * concomitant diagnosis of an active neoplasia, or * patients who had previously received radiotherapy, * end organ failure.
antibiotic therapy in infections of the diabetic foot syndrome

Conditions: Diabetic Foot Infection

Summary: this retrospective study examines the surgical and antibiotic treatment of diabetic foot syndrome infections treated at the university hospital basel since 2019. it analyses the implementation of the hospital in-house guidelines published in 2019 with regard to antibiotic therapy in diabetic foot infections, taking into account clinical, microbiological and histopathological criteria. the defined endpoints are (i) fully compliant with internal policies, (ii) partially compliant with internal policies, and (iii) not compliant with internal policies. the recording of these proportions is descriptive.

this retrospective study examines the surgical and antibiotic treatment of diabetic foot syndrome infections treated at the university hospital basel since 2019. (in 2019 the departments of infectiology and orthopedics at the university hospital basel published recommendations with regard to the duration of antibiotic therapy in infections of the diabetic foot syndrome. this depends on whether a surgical intervention was performed and takes into account both the microbiological and the histopathological samples). data that are routinely collected in everyday clinical practice and stored in the hospitals' medical records will be evaluated. the aim of this research project is to check the implementation of these recommendations. inadequate use of antibiotics should thus be recognized. the study has the aspect of quality control.

Eligibility criteria:
inclusion criteria: * soft tissue infection or bone infection (incl. osteomyelitis) in diabetic foot syndrome * inpatient stay at the university hospital basel between january 1st, 2019 and december 31st, 2021 * surgical intervention (amputation and/or debridement) * signed general consent exclusion criteria: * datasets without a diagnosis of the diabetic foot * no surgical intervention performed (amputation and/or debridement) * surgical interventions performed by disciplines other than orthopaedics/traumatology (e.g. vascular surgery) * infections in osteosynthesis material (implant or fracture-associated infections)

Keywords: diabetic foot syndrome antibiotic therapy soft tissue infection osteomyelitis bone infection
a phase i/ii clinical trial with sens-501 in children suffering from severe to profound hearing loss due to otoferlin (otof) mutations

Conditions: OTOF Gene Mutation; DFNB9; Congenital Deafness; Hearing Disorders; Ear Diseases; Otorhinolaryngologic Diseases; Deafness; Hearing Loss, Sensorineural

Summary: this study intends to assess safety, tolerability, and efficacy of sens-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the otoferlin gene.

it is a multicenter, adaptive open-label, non-randomized, dose-escalation, and expansion study to assess safety, tolerability, and efficacy following intracochlear administration of sens-501.

Eligibility criteria:
inclusion criteria: * children (male or female) ≥ 6 to ≤ 31 months at the time of inclusion * severe to profound hearing loss assessed by auditory brainstem response (abr) * biallelic mutation in the otoferlin gene * presence of otoacoustic emissions (oaes) * documented normal cochlea and internal auditory canals * patients with intact vestibular function exclusion criteria: * history of chronic, acute, or major disease, or unspecified reasons, that in the opinion of the investigator, makes the participant unsuitable for participation in the study or constitutes an unacceptable risk. * have been dosed in a previous gene therapy clinical trial * patients with a prior or current cochlear implant * any contraindication to the surgery determined by the surgeon or anesthesia determined by the anesthesiologist, or designee, or history of therapy known as ototoxic (e.g., cisplatin, high dose and long treatment with aminoglycosides, etc.) for an extended period (more than 2 weeks). * participation in any other interventional clinical trial * any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the participant or would preclude the participant from successful completion of the study or might interfere with the evaluation of study treatment * anticipated noncompliance with the protocol requirements

Keywords: otof gene mutation hearing impairment deafness otoferlin audiogene hearing loss dfnb9 hearing disorder cochlear implant sens-501 congenital hearing loss gene therapy
microphage s. aureus / mssa / mrsa blood culture beta trial

Conditions: Bacteremia; Staphylococcal Infection; Sepsis; Infection

Summary: in-vitro identification of s. aureus, methicillin-sensitive s. aureus (mssa), and methicillin-resistant s. aureus (mrsa) from positive blood cultures by microphage's bacteriophage-based diagnostic platform.

this is a multi-center, preclinical study to investigate the effectiveness of the performance of microphage s. aureus / mssa/mrsa test direct for blood culture. there will be no patient consent, as this is a laboratory performance study on leftover specimens. the microphage test will be compared to site standards (gold standard) and market-available tests with similar indications (comparators). microphage will require data to be collected at 4 hours and 5 hours following the start of the microphage test. the study will last 2-3 months, depending on the accrual rate of the institution.

Eligibility criteria:
inclusion criteria: * over 18 years of age. * blood culture positive, of any of the following bottle types: * bd bactec standard aerobic and anaerobic, * bd bactec plus aerobic and anaerobic, * biomerieux bact/alert standard aerobic and anaerobic, * biomerieux bact/alert fan aerobic and anaerobic. exclusion criteria: * bd bactec lytic, pediatric, or other bottle types not listed above. * biomerieux pediatric fan or other bottle types listed above. * trek bottles. * specimens from patients under 18 years of age.

Keywords: blood culture staphylococcus aureus bacteremia mrsa mssa microphage
poststroke depression of clinical trial registration

Conditions: Stroke; Depression

Summary: the investigators aim to explore the relationship between gut microbiota composition and earlier poststroke depression via 16s rrna sequencing.

in this study, patients with first ever acute ischemic stroke were studied. according to the psychological assessment, patients were divided into two groups according to whether or not there was a psd at the earlier stage of stroke. clinical biological data and blood and feces samples were collected. firstly, 16srdna sequencing was used to study the difference in the composition and diversity of intestinal microbial communities in the two groups of patients. then the two groups selected individual representative samples and conducted macro genome sequencing. at the same time, by analyzing the correlation between the intestinal flora and the clinical risk factors and neurotransmitters in early psd patients, the key functional bacteria related to psd were identified.

Eligibility criteria:
inclusion criteria: * diagnosed with the first ever acute ischemic stroke occurring within 2 weeks and were confirmed by ct or mri, * has no history of depression or use of antidepressants or antipsychotics, * were competent to consent to take part in this research. exclusion criteria: * significant acute or severe illness such as infection,heart failure and tumor, * previous diagnosis of depression or other mental disorder or who had recently accepted antidepressants or antipsychotics, * antibiotics in the last two weeks, * severe aphasia or dysarthria,irritable bowel syndrome,asthma,and pregnant or lactating women, * a previous history of neurological illness including ad and pd， * inflammatory bowel disease，

Keywords: ischemic stroke depression intestinal microbiota
the use of drospirenone/estetrol, nomegestrol acetate/estradiol and ethinylestradiol/dienogest in random start rapid endometrial preparation

Conditions: Endometrial Polyp; Endometrial Diseases

Summary: the presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. we explored the efficacy of random started 14-day administration of drospirenone/estetrol or nomegestrol acetate/estradiol or ethinylestradiol/dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy.


Eligibility criteria:
inclusion criteria: * patients with endometrial polyps. exclusion criteria: * patients with other endometrial pathologies.

Keywords: hysteroscopy endometrial preparation
safety study of ranibizumab eye injections to treat choroidal neovascularization that was caused other than by age-related macular degeneration.

Conditions: Choroidal Neovascularization

Summary: the purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.


Eligibility criteria:
inclusion criteria: * active choroidal neovascularization exclusion criteria: * pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Keywords: choroidal neovascularization choroidal neovascularization not related to age-related macular degeneration
rifaximin and propranolol combination therapy versus propranolol monotherapy in cirrhotic patients

Conditions: Liver Cirrhosis; Portal Hypertension

Summary: to reduce portal pressure, the only recommended medication is nonselective beta blocker(nsbb). however, nsbb has some limitation to apply clinically because of poor response rate and compliance. recent literature has supported the role of bacterial translocation as a mediator of splanchnic vasodilatation and portal hypertension. this stimulates the release of pro-inflammatory cytokines and the activation of the vasodilator no resulting in a more pronounced deterioration of the baseline hyperdynamic circulatory state. selective gut decontamination with rifaximin can induce inhibition of bacterial translocation and associated worsening of portal hypertension. the investigators hypothesized that rifaximin plus nsbb could result in decrease of portal pressure in cirrhotic patients with esophageal varices.


Eligibility criteria:
inclusion criteria: * liver cirrhosis:diagnosed based on histology or unequivocal clinical, sonographic, and laboratory findings * 19≤age≤75 * hepatic venous pressure gradient \> 12 mmhg * informed consent exclusion criteria: * shock status requiring vasopressor * active infection, for example spontaneous bacterial peritonitis * acute renal failure patients of any cause * clinically relevant coronary artery disease(nyha functional angina classification iii/iv),congestive heart failure nyha iii/iv), clinically relevant cardiomyopathy, history of myocardial infarction in the past 12 months * poorly controlled hypertension (bp 150/100mmhg) * hepatocellular carcinoma * history of another primary malignancy ≤ 3years * medical or psychological conditions that would not permit the subject to complete thte study or sign informed consent * pregnancy or lactation period * serum creatinine ≧ 6mg/dl * involvement in the conduct of other study within 30 days * known hypersensitivity to rifaximin or propranolol * dysarrhythmia, inappropriate for study on investigator's judgment

Keywords: liver cirrhosis portal hypertension hepatic venous pressure gradient rifaximin
evaluation of a couple-based physical activity intervention

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this clinical trial tests how well a couple-based physical activity (pa) intervention, mates in motion, works in patients undergoing hematopoietic cell transplantation (hct) or chimeric antigen receptor t-cell therapy (cart) and their care giving partners to be more physically active. mates in motion provides training in communication skills and behavior change techniques to help hct patient-caregiver dyads support one another in adoption and maintenance of pa. this study may help researchers determine if a couple-based pa intervention improves pa, physical endurance and global physical health among patient-care giver dyads undergoing hct or cart.

primary objectives: i. to determine feasibility of recruitment, adherence, and retention of a couple-based pa intervention in a pilot randomized controlled trial (rct). ii. determine acceptability of the intervention (multiple dimensions of treatment satisfaction). iii. describe changes in pa, physical endurance, and global physical health from baseline to follow-up as a function of randomized condition. outline: patient-caregiver dyads are randomized to 1 of 2 arms. arm i: dyads participate in the mates in motion program consisting of weekly sessions to train couples in the use of communal coping strategies to support one another in achieving pa goals and skill building focus on instruction and practice in effective communication, with emphases on adaptive speaking, responsive listening, and joint decision-making and problem-solving around pa over 8 weeks. patient-partner dyads receive weekly step-count goals, complete walk-tests and questionnaires and wear an actigraph device and garmin activity tracker on study. arm ii: patient-partner dyads wear an actigraph device, compete walk-tests and questionnaires on study. dyads receive usual care on study. dyads receive a garmin activity tracker at the end of the study.

Eligibility criteria:
inclusion criteria: * patients: age 18 years or older * patients: scheduled to receive an autologous or allogeneic hematopoietic cell transplant (hct) or chimeric antigen receptor (car)-t cell therapy * patients: able to speak and comprehend english * patients: being married or in a committed (self-defined) cohabiting same- or opposite-sex relationship * patients: physician-approved for a walking program * caregivers: age 18 years or older * caregivers: able to speak and comprehend english * caregivers: married to or in a committed, cohabiting, same- or opposite-sex relationship with the patient * caregivers: able to participate in a walking program exclusion criteria: * none per se beyond the converse of the inclusions listed above, for example, age younger than 18 years and non-partnered
intrapleural nebulization of bupivacain to reduce postoperative pain

Conditions: Lung Diseases

Summary: thoracic surgery is now common and as other surgeries evolution of minimally invasive techniques is employed. video-assisted thoracic surgery (vats) produces little scar but may produce severe pain that may affect the pulmonary function. many procedure was developed like intercostal nerve block which require injections at multiple levels, insertion of local anaesthetic (la) in the surgical drain but that was dangerous due to the large amount of la and not sufficient to completely eliminate pain. bupvicaine nebulization, through surgical port which won't make any other wound, thought to be sufficient because nebulization will enable us better distribution and less amounts of la. bupvicaine is local anaesthetic amide group that works by blocking sodium channels thus preventing progression of action potential.


Eligibility criteria:
inclusion criteria: * patients that reach american socity of anesthesiologist class 1-3 * scheduled for vats surgery under general anesthesia. exclusion criteria: * ● allergy to local anesthetics * patient with pleural inflammation due to recent pneumonia * patients who are unable or unwilling to perform spirometer test * renal dysfunction: (elevated creatinine \> 2 mg\\dl) * hepatic dysfunction: (elevated hepatic enzymes three times above normal value) * history of addiction
clinical study on auricular points sticking plus chinese medication for hot flashes in breast cancer women

Conditions: Breast Cancer; Hormonal Therapy; Hot Flashes; Acupuncture

Summary: object:the aim of this study was to investigate the effectiveness of sticking and massaging auricular points for the management of hot flashes in postoperative breast cancer patients.

patients and methods a randomized controlled trial is conducted by comparing effectiveness of sticking and massaging auricular points relieving hot flashes in women with breast cancer versus placebo auricular points. a total of 92 women(still recuiting) with breast cancer, who were under hormonal therapy were randomly assigned and the allocation ratio was 1:1. both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.in addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments. the primary outcome was hot flash score(hfs)at the end of treatment (week 12), calculated as the frequency multiplied by the average severity of hot flashes.the secondary outcomes were climacteric symptoms and quality of life, measured by the greene climacteric scale(gcs)and menopause quality of life scales(menqol)as well as serum estradiol(e2), follicle-stimulating hormone(fsh) and beta-endorphin(β-ep).expectation and satisfaction of treatment effect and safety were also evaluated.

Eligibility criteria:
inclusion criteria: * primary breast cancer after surgical treatment, pathologically diagnosed malignant breast epithelial tumors (breast cancer), immunohistochemistry showed pathological type of estrogen receptor (er) and / or progesterone receptor (pr) positive. * participants should be currently receiving endocrine therapy with oral administration of serms(selective estrogen receptor modulators) only. * participants should be suffered from perimenopausal symptoms,which is the sudden onset of facial skin flushing, sweating, began from chest and neck,often lasts a few seconds to several minutes and then subsided after center body temperature drops, the associated symptoms of heart palpitations, anxiety, impatience and even a sense of panic, and even wake up at night. the interval between the two attacks is more than 10 minutes. * hot flashes occurs during endocrine therapy of breast cancer * kps score \>60 score \>2 and ecog * hot flashes (greater than or equal to 3 times the number of hot flashes per day) * symptoms persist for more than 2 weeks exclusion criteria: * participants who have uncontrolled diabetes, hyperthyroidism and hypertension and in patients with pheochromocytoma * abnormal blood routine, liver and kidney damage (the index is greater than 1.2 times the upper limit of normal value) * pregnant or lactating women, persons with mental disorders * participants with other cancers * participants are participating in other clinical trials * current chemotherapy treatment period has not yet completed * taking corticosteroids or sex hormone treatment.
research on the characteristics and application of lactobacillus rhamnosus x253 as oral probiotics

Conditions: Dental Caries

Summary: the aim of the study is to study the application of lactobacillus rhamnosus x253 as oral probiotics by the way of a randomised, double blinded, parallel, placebo-controlled clinical trial, and to eto detect the changes in oral flora of volunteers, and judge the improvement effect of x253 lozenges on the human oral flora.

population experiments were carried out, and quantitative real-time pcr was used to detect the expression level of the target strains in volunteers' oral, high-throughput sequencing technology to detect the changes in oral flora of volunteers, and judge the improvement effect of x253 lozenges on the human oral flora. the effects of x253 lozenges on the volunteers' oral odor, defecation frequency and gum bleeding was surveyed and conuted by questionnaire.

Eligibility criteria:
1. age: 18 years old and above; 2. gender: there is no restriction on men or women (women are not pregnant); 3. keep more than 20 original teeth in the oral cavity; 4. have not had periodontal treatment, tooth whitening (ceramic veneer, cold light whitening), orthodontics, etc. in the past 6 months; 5. no oral topical medication (such as mouthwash, watermelon frost) within 1 month; 6. no dental filling plan in the next 2-6 weeks; 7. have not taken antibiotics (such as amoxicillin, cephalosporin, roxithromycin, ofloxacin, etc.), hormones (such as glucocorticoids, thyroid hormones, insulin, etc.) and immunosuppressive agents(such as dexamethasone, methylprednisolone, sirolimus, azathioprine) in the past half month; no taking plan for antibiotics (such as amoxicillin, cephalosporin, roxithromycin, ofloxacin, etc.), hormones (such as glucocorticoids, thyroid hormones, insulin, etc.) and immunosuppressive agents (such as dexamethasone, methylprednisolone, sirolimus, azathioprine) within the next 2-6 weeks; 8. no obvious abnormal occlusal relationship (the corresponding relationship between the upper jaw and the lower jaw is not normal, and the chewing efficiency is low).